In the 3rd quarter issue of termsheet last year, we predicted a significant increase in pharmaceutical M&A deal values for 2015. In our latest white paper 'Trends in the CMO Landscape' we demonstrate the impact this increase in deal values has had on the...

The pharmaceutical small molecule API manufacturing industry is now experiencing a period of rapid change. This change is being driven by factors such as the changing nature of the drugs being made, expiry of patents covering the top-selling pharmaceuticals, the...

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will benefit from a drug...

Deal making is the lifeblood of the pharmaceutical sector. In- and out-licensing and other types of agreements are key mechanisms by which intellectual property (IP) of innovative products and technologies is transferred between companies for achievement of...

The life sciences industry has never seen such an intensity of deal-making, especially that of licensing, than in the past six years. Some of the reasons for this are quite evident: growing pharmaceutical companies have greater pipeline needs, a spate of patent...

The late 1990s and early years of the current decade saw a number of mega-mergers between companies, which defined the current shape of the pharmaceutical industry, and have established a hierarchy of companies commonly referred to as `big pharma'. In recent years,...

The ophthalmology drug segment continues to shine brightly with a number of deals announced in November such as Genentech’s partnering with Novartis to split ex-US rights to Ophthotech’s eye drug, which could be worth more than $1 billion. Allergan,...

The ‘antibiotic crisis’ is rarely out of the news these days, with headlines issuing dire warnings that the rise in resistance to anti-microbial drugs could result in a return to the medical dark ages. In order to tackle this problem, various initiatives have been...

The ophthalmology device segment has experienced robust transaction activity with over 500 transactions taking place between January 2010 and the end of the first quarter in 2015. In this white paper we look at the range of transaction activity by type, geography and...

Leading CMOs are developing acquisition strategies based on reinforcing their customer base, expanding their geographic reach and broadening their capabilities. Similarly, customers are increasingly demanding simpler sourcing models that can deliver speed and...

Immuno-oncology is the latest and perhaps the most exciting development in cancer and immunotherapy. In this white paper we take a look at the history and the recent deal activity and at why we can expect this to be a hot area for deal making in the immediate future....

Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, pharma deal-making occupies an intermediate position. One can easily argue...

It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma are in the attractive position that they get thousands of unsolicited licensing...

It’s useful to review deal trends periodically to gain insight in how behaviours are changing from the perspective of numbers and value of deals as well as how emphasis shifts from one therapeutic area to another. The majority of small and mid-size development...